Pau M. F.
- Country
- Spain
- Department
- 172402: Hematologia
Research Overview
- Phase 1 Evaluation of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase Mutations
- Phase 1 Dose Escalation Study of SGR-2921 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Phase 1 Open-Label Dose Escalation and Expansion Study of CLN-049 in Acute Myeloid Leukemia with Measurable Residual Disease
Data & Insights
Has run more than one trial at 194 of 348 partner sites.
Specializations
Acute Myeloid Leukemia Research
The investigator specializes in treating relapsed and refractory acute myeloid leukemia (AML), with particular focus on developing novel therapeutic approaches for patients who have exhausted standard treatment options.
- Menin-MLL inhibitor studies
- FLT3 targeted therapies
- CD123-positive AML treatments
Myelodysplastic Syndromes
Conducts research in higher-risk myelodysplastic syndrome (MDS) and its various manifestations, exploring innovative therapeutic combinations and targeted approaches.
- RARA-positive MDS studies
- Novel combination therapies
- Venetoclax-based treatments
Advanced Hematologic Malignancies
Investigates treatments for various blood cancers including mixed-phenotype leukemias and myeloproliferative neoplasms, with emphasis on molecular targeted therapies.
- IDH mutation studies
- Bispecific antibody research
- Immunotherapy approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.